Emergent BioSolutions Inc. (EBS) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 15 analysts50.0% Below Target
EBS trades 50.0% below Wall Street's consensus target of $12.00.
Current Price$8.00
Average Target$12.00
Low$12.00
Median$12.00
High$12.00
Analyst Target Range
Forward P/E24.6x
(Fair)
PEG Ratio—
Implied Growth-67.6%
(Declining)
Analyst Spread0.0%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes EBS achieves its forward estimates and maintains a stable P/E multiple of 24.6x. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
EBS Price Target Analysis
Updated June 22, 2026As of June 22, 2026, Emergent BioSolutions Inc. (EBS) has a Wall Street consensus price target of $12.00, based on estimates from 15 covering analysts. With the stock currently trading at $8.00, this represents a potential upside of +50.0%. The company has a market capitalization of $413M.
Analyst price targets range from a low of $12.00 to a high of $12.00, representing a 0% spread in expectations. The median target of $12.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EBS trades at a trailing P/E of 8.6x and forward P/E of 24.6x. Analysts expect EPS to grow -67.6% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+42.6%
Industry Consensus
Avg Forward P/E
13.3x
(Value)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SIGASIGA Technologies, Inc. | $310M | $4.32 | — | — | Buy | 2.5x | 1 |
 PRGOPerrigo Company plc | $1.4B | $10.25 | $36.20 | +253.2% | Hold | 4.8x | 36 |
 BRKRBruker Corporation | $8.7B | $57.23 | $47.67 | -16.7% | Buy | 27.0x | 32 |
 ABCLAbCellera Biologics Inc. | $1.7B | $5.53 | $7.50 | +35.6% | Buy | — | 11 |
 PCRXPacira BioSciences, Inc. | $878M | $22.33 | $32.00 | +43.3% | Hold | 7.8x | 36 |
 PFEPfizer Inc. | $143.5B | $25.22 | $26.75 | +6.1% | Hold | 8.5x | 39 |
 MRKMerck & Co., Inc. | $281.2B | $113.87 | $131.58 | +15.6% | Buy | 22.2x | 37 |
 JNJJohnson & Johnson | $550.4B | $228.39 | $251.55 | +10.1% | Buy | 19.7x | 40 |
 BAXBaxter International Inc. | $10.3B | $19.89 | $20.71 | +4.1% | Hold | 10.4x | 36 |
 MCKMcKesson Corporation | $90.2B | $750.63 | $994.86 | +32.5% | Buy | 17.0x | 31 |
EBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
What is the EBS stock price target for 2026?
The consensus Wall Street price target for EBS is $12, representing 50.0% upside from the current price of $8. With 15 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is EBS a buy, sell, or hold?
EBS has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $12 implies 50.0% upside from current levels.
Is EBS stock overvalued or undervalued?
EBS trades at a forward P/E of 24.6154x, representing a moderate valuation. With analysts targeting $12 (50.0% implied move), the stock appears reasonably valued with upside.
How high can EBS stock go?
The most bullish Wall Street analyst has a price target of $12 for EBS, while the most conservative target is $12. The consensus of $12 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover EBS stock?
EBS is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the EBS stock forecast?
The 12-month EBS stock forecast based on 15 Wall Street analysts shows a consensus price target of $12, with estimates ranging from $12 (bear case) to $12 (bull case). The median consensus rating is "Buy".
What is EBS's forward P/E ratio?
EBS trades at a forward P/E ratio of 24.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 8.6x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy EBS stock?
Wall Street analysts are very optimistic on EBS, with a "Buy" consensus rating and $12 price target (50.0% upside). 11 of 15 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do EBS price targets vary so much?
EBS analyst price targets range from $12 to $12, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $12 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare